We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Redhill Biopharma Ltd | NASDAQ:RDHL | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.0007 | -0.16% | 0.4498 | 0.4499 | 0.458 | 0.4674 | 0.4498 | 0.4674 | 173,871 | 21:27:58 |
From May 2019 to May 2024
By Michael Dabaie
RedHill Biopharma Ltd. American depositary receipts were up 14% to $5.23 in late morning trading.
Before the market opened, the biopharmaceutical company focused on gastrointestinal diseases said it had completed the acquisition of the global rights, excluding Europe, Canada and Israel, to Movantik for the treatment of opioid-induced constipation from AstraZeneca PLC.
The company said it is expanding the promotion of Movantik with its current sales force of about 100 representatives.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 02, 2020 12:10 ET (16:10 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Redhill Biopharma Chart |
1 Month Redhill Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
